Lovastatin contraindications: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Protected "Lovastatin contraindications": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)))
 
(3 intermediate revisions by one other user not shown)
Line 1: Line 1:
__NOTOC__
#redirect [[Lovastatin#Contraindications]]
{{Lovastatin}}
{{CMG}}; {{AE}} {{SS}}
 
==Contraindications==
 
The use of Altoprev® is contraindicated in the following conditions:
 
*Concomitant administration of strong CYP3A inhibitors [see Warnings and Precautions, Skeletal Muscle Effects (5.1) and Drug Interactions (7.1)].
*Concomitant administration of [[erythromycin]] [see Warnings and Precautions, Skeletal Muscle Effects (5.1) and Drug Interactions (7.1)].
*[[Hypersensitivity]] to any component of this product [see Adverse Reactions (6.1)]. Active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels [see Warnings and Precautions, Liver Enzyme Abnormalities (5.2)].
*Women who are pregnant or may become pregnant. Because HMG-CoA reductase inhibitors decrease [[cholesterol]] synthesis and possibly the synthesis of other biologically active substances derived from [[cholesterol]], Altoprev® may cause fetal harm when administered to pregnant women. Additionally, there is no apparent benefit to therapy during pregnancy, and safety in pregnant women has not been established. If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus and the lack of known clinical benefit with continued use during pregnancy [see Use in Specific Populations (8.1) and Nonclinical Toxicology (13.1)].
*Nursing mothers. Because another drug in this class passes into breast milk, and because [[HMG-CoA]] reductase inhibitors have the potential to cause serious adverse reactions in nursing infants, women who require Altoprev® treatment should be advised not to nurse their infants. [see Use in Specific Populations (8.3)].<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = ALTOPREV (LOVASTATIN) TABLET, EXTENDED RELEASE [SHIONOGI INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e8b6ccc2-e6e7-45fd-ab66-c312bcbe2b01 | publisher =  | date =  | accessdate = 13 February 2014 }}</ref>
 
==References==
{{Reflist|2}}
 
{{Statins}}


[[Category:Statins]]
[[Category:Statins]]
[[Category:Carboxylate esters]]
[[Category:Carboxylate esters]]
[[Category:Lactones]]
[[Category:Lactones]]
[[Category:Cardiovascular Drug]]
[[Category:Cardiovascular Drugs]]
[[Category:Drug]]
[[Category:Drug]]

Latest revision as of 16:37, 20 August 2015